SCHEMBL422509

SCHEMBL422509

O=C(O)c1ccc(-c2ccc(F)cc2)s1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.72
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
POLB P06746 1/20 0.72
KDM4E B2RXH2 3/20 0.67
NPC1 O15118 2/20 0.67
ALDH1A1 P00352 2/20 0.67
HPGD P15428 1/20 0.67
MAPT P10636 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
GAA P10253 1/20 0.61
HPGDS O60760 1/20 0.59
ESRRG P62508 3/20 0.58
PTPN2 P17706 1/20 0.58
PTPN11 Q06124 1/20 0.58
HDAC6 Q9UBN7 2/20 0.56
HDAC1 Q13547 2/20 0.56
DAO P14920 1/20 0.55
MKNK1 Q9BUB5 1/20 0.54
MKNK2 Q9HBH9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3576074 0.98 RAB9A (0.70) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL27983242 0.88 RAB9A (0.67) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL16595405 0.87 RAB9A (0.61) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL2715877 0.85 RAB9A (0.63) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL27358085 0.85 IKBKB (0.69) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL2491267 0.84 RAB9A (1.00) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL10963422 0.84 RAB9A (0.72) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL2083801 0.84 MEN1 (0.72) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL29906336 0.84 RAB9A (0.79) RAB9AMEN1KMT2APOLBKDM4E
SCHEMBL3749139 0.84 HPGDS (0.69) RAB9AMEN1KMT2APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105461680-B A kind of synthetic method of 2- (4- fluorophenyls) thiophene 苏州毕奇尔生物科技有限公司 2018-06-22 CN claimed
CN-105461680-A Synthetic method of 2-(4-fluorophenyl) thiophene SUZHOU BICHAL BIOTECHNOLOGY CO LTD 2016-04-06 CN claimed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US claimed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP claimed
US-7109243-B2 Inhibitors of cathepsin S IRM LLC (BM) 2006-09-19 US claimed
EP-1237849-A1 ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE UNIVERSITY COLLEGE LONDON (GB) 2002-09-11 EP claimed
WO-2001032604-A1 ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE UNIVERSITY COLLEGE LONDON (GB) 2001-05-10 WO claimed
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2022-06-30 US disclosed
US-11269251-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2022-03-08 US disclosed
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
CN-109868134-A A kind of particle and preparation method thereof TCL集团股份有限公司 2019-06-11 CN disclosed
CN-109868133-A A kind of particle and preparation method thereof TCL集团股份有限公司 2019-06-11 CN disclosed
CN-109868132-A A kind of particle and preparation method thereof TCL集团股份有限公司 2019-06-11 CN disclosed
WO-2001032604-A1 ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE UNIVERSITY COLLEGE LONDON (GB) 2001-05-10 WO disclosed
WO-2001025229-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-04-12 WO disclosed
EP-0259972-B1 HETEROCYCLIC PROPENE AMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS LILLY INDUSTRIES LIMITED (GB) 1993-07-14 EP disclosed
CN-1021050-C PREPARING METHOD FOR BUTYRUMID DERIVATIVE LILLY INDUSTRIES LTD (GB) 1993-06-02 CN disclosed
CN-1059142-A New thiophene derivant FUJISAWA PHARMACEUTICAL CO (JP) 1992-03-04 CN disclosed
CN-87105515-A Derivatives of phenylbutenamide compounds and preparation method thereof 1988-03-23 CN disclosed
EP-0259972-A2 Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals LILLY INDUSTRIES LIMITED (GB) 1988-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RACK1, RRBP1, RPL30 RAB9A 1823/4885MEN1 4218/4885KMT2A 2968/4885
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R RAB9A 1154/4885MEN1 550/4885KMT2A 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.